Wings, fries and tacos come first when pharma reps order for docs

Carly Helfand It's all about Southern, American and Mexican food–at least, when pharma reps are ordering in for events at doctors' offices. FiercePharma News

‘Lies, deceit and fraud’: Martin Shkreli blasted by the feds for Ponzi scheme

John Carroll In addition to earning global notoriety over the past few months for price gouging on old drugs, Martin Shkreli also blazed an alleged 5-year trail of fraud that includes ...

Baxalta wins FDA approval with a treatment for a rare bleeding disease

Damian Garde Baxalta picked up FDA approval for a drug that treats von Willebrand disease, a rare inherited bleeding disorder that results from a missing protein. FierceBiotech News

Catalent stops production at French plant, brings in law enforcement after it twice detects tampering

Eric Palmer U.S.-based Catalent has halted production at a drug manufacturing facility in France at the request of regulators after several incidents in which it appears someone within ...

Boehringer wins FDA approval for its Pradaxa antidote with eyes on a bigger market share

Damian Garde Boehringer Ingelheim picked up an FDA nod for an injection designed to reverse the effects of its blockbuster anticoagulant Pradaxa, marking the first approval for an antidote ...

Zafgen finally breaks its silence, says it’s probing death of a patient

John Carroll More than two days after Zafgen's stock started to get crushed under the heavy weight of speculation surrounding its sudden decision to cancel a roadshow presentation ...

The Shkreli scandal leaves a big mess for biotech to clean up

John Carroll The industry now has to deal with the fact that drug pricing has taken center stage in presidential politics. And the story of Daraprim, Martin Shkreli and price gouging ...

With $1B in VC cash, Intarcia is happy to stay out of the IPO scrum

Damian Garde Intarcia Therapeutics is rolling toward an FDA application with its long-acting diabetes treatment, but despite the ready availability of IPO cash for drug developers, ...

Valeant doubles size of its HQ as deal spree continues

Carly Helfand Serial buyer Valeant is expanding quickly, and to keep up, it's expanding its office space, too. The Canadian pharma has leased another 310,000 square feet at Somerset ...

Patient education ‘useless’ when it comes to Eliquis adherence: study

Carly Helfand Good news for partners Bristol-Myers Squibb and Pfizer: In a Phase IV study of their new-age anticoagulant, Eliquis, atrial fibrillation patients posted adherence rates ...

The FDA offers a controversial solution to the biosimilars name game

John Carroll The industry has been wrestling for years now over naming the first wave of biosimilars building on the coast of the American drug industry. A lot of companies that develop ...

Celgene nails down $7.2B takeover of Receptos

Eric Palmer Celgene Thursday reported that it had completed its $ 7.2 billion buyout of Receptos. Celgene agreed to pay $ 232 per share for the San Diego-headquartered company, a ...
Page 3 of 5012345...102030...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS